Clinical trialPhase 2Recruiting
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 19 July 2020
- Expected end
- July 2027
- Enrollment
- 72 participants
- Sites
- 1
- Primary outcomes
- Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.
- Sponsor
- Other
- Results posted
- No
- Last update
- 27 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
Detailed description public domain (ClinicalTrials.gov)
Detailed Description: The investigators have developed \[68Ga\]CBP8, a gallium-68 labeled collagen binding PET imaging probe, which selectively binds collagen type I. Collagen deposition is a pivotal event in several human conditions including radiation induced lung injury and in response to radiation therapy in pancreatic cancer. The investigator's studies in murine models of lung injury including radiation induced lung injury showed that \[68Ga\]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles with high target uptake and low retention in background tissues and organs. \[68Ga\]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis. \[68Ga\]CBP8 showed high specificity for pulmonary fibrosis and high target:background ratios in diseased animals. In addition, \[68Ga\]CBP8 could be used to monitor response to treatment. Ex vivo analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) supported the animal findings. The investigators have conducted preliminary studies in humans with IPF and demonstrated a significant increase in \[68Ga\]CBP8 signal in subjects with IPF vs healthy controls. The investigators thus aim to evaluate \[68Ga\]CBP8 in human subjects with radiation induced lung injury and in patients undergoing radiation therapy for pancreatic cancer: To establish the ability of \[68Ga\]CBP8-PET to detect radiation-induced fibrosis in lung or pancreatic cancer patients through the course of disease development with repeated measures, and correlate signal with standard measures of radiation induced tissue injury such as HRCT or MRI.